Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.

Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.

Item
http://www.wikidata.org/entity/Q33369258
High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.New advances in DPYD genotype and risk of severe toxicity under capecitabine.Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment.Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.Capecitabine-induced cardiotoxicity: case report and review of the literature.Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.Delayed Presentation of DPD Deficiency in Colorectal Cancer.Pharmacogenetics and breast cancer management: current status and perspectives.Nucleoside analogs: ready to enter the era of precision medicine?Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients.Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
P2860

Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.

Item
http://www.wikidata.org/entity/Q33369258
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Toxic death-case after capecit ...... ine deshydrogenase deficiency.
@ast
Toxic death-case after capecit ...... ine deshydrogenase deficiency.
@en
type
label
Toxic death-case after capecit ...... ine deshydrogenase deficiency.
@ast
Toxic death-case after capecit ...... ine deshydrogenase deficiency.
@en
prefLabel
Toxic death-case after capecit ...... ine deshydrogenase deficiency.
@ast
Toxic death-case after capecit ...... ine deshydrogenase deficiency.
@en
P1433
P1476
P2093
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P356
P1433
P1476
Toxic death-case after capecit ...... ine deshydrogenase deficiency.
@en
P2093
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698